About this Research Topic
This Research Topic aims to collect studies to update and discuss the recent advances in stereotactic radiotherapy addressing important technical and clinical questions on LINAC-based hypofractionated high dose delivery for the treatment of oligometastatic disease. Indication, treatment preparation including advanced imaging for target definition of SBRT, SRT for diverse cancer types such as prostate, lung, breast, kidney, liver, pancreatic malignancies, and less frequent tumors such as melanoma, sarcoma could be studied in different clinical situations like early-stage cancer, oligo-site progression and local recurrence in pretreated location. Optimization of treatment delivery (time and volume determination, on-board and repeated imaging, target motion monitoring, and management) can be evaluated along with outcome results.
We welcome submissions on, but not limited to, the following themes:
- Positioning, immobilization, and target motion detection in the preparatory phase of SABR, SRS
- Use of advanced imaging for target definition, and motion follow up
- Fractionation, timing, and dosage of radiation
- Radiation delivery and imaging techniques, quality assurance
- Evaluation of the treatment outcome in correlation to the clinical factors and radiation parameters
Original Research, in the above-listed topics, is preferred as the manuscript type.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Keywords: SRT, brain metastases, Lung cancer, Metastatic llung cancer, Prostate cancer, Melanoma malignum, oligometastatic disease, stereotactic ablative body radiotherapy (SABR), stereotactic body radiation therapy (SBRT)
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.